Based in Indianapolis, Indiana, Eli Lilly and Company is a pharmaceutical manufacturer engaged in the discovery, development, and commercialization of human pharmaceutical products across multiple therapeutic areas. The company operates globally, with significant presence in the United States, Europe, China, Japan, and other international markets.
The company's product portfolio spans three primary therapeutic segments. Its cardiometabolic health business includes insulin formulations such as Humalog and Humulin, along with newer agents for type 2 diabetes including Jardiance, Mounjaro, and Trulicity, as well as Zepbound for obesity management. The oncology segment comprises agents including Cyramza for gastric cancers, Erbitux for colorectal and head and neck cancers, Jaypirca for hematologic malignancies, Retevmo for metastatic non-small cell lung cancer, and Verzenio for breast cancer. The immunology segment features Olumiant for rheumatoid arthritis and atopic dermatitis, Taltz for psoriatic conditions, Ebglyss for severe atopic dermatitis, and Emgality for migraine prevention. The company also markets Kisubla for Alzheimer's disease.
With approximately 50,000 full-time employees, Eli Lilly operates as a large-scale multinational pharmaceutical manufacturer. The company maintains research collaborations and licensing agreements with various pharmaceutical and biotechnology partners to expand its pipeline and marketed product offerings.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $22.95 | $23.00 | +96.0% | |
| 2024 | $11.71 | $11.76 | +101.9% | |
| 2023 | $5.80 | $5.82 | -15.9% | |
| 2022 | $6.90 | $6.93 | +12.7% | |
| 2021 | $6.12 | $6.15 | -9.9% | |
| 2020 | $6.79 | $6.82 | +314.0% | |
| 2019 | $1.64 | $1.64 | +49.1% | |
| 2018 | $1.10 | $1.11 | +169.6% | |
| 2017 | $-1.58 | $-1.58 | -316.4% | |
| 2016 | $0.73 | $0.73 | +62.2% | |
| 2015 | $0.45 | $0.45 | +12.5% | |
| 2014 | $0.40 | $0.40 | -40.3% | |
| 2013 | $0.67 | $0.68 | -81.7% | |
| 2012 | $3.66 | $3.67 | -6.2% | |
| 2011 | $3.90 | $3.90 | -14.8% | |
| 2010 | $4.58 | $4.58 | — | |
| 2009 | — | — | — |